IGM Biosciences Ownership
| IGMS Stock | USD 9.40 0.51 5.74% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 60.4 M | Current Value 60.7 M | Avarage Shares Outstanding 38.1 M | Quarterly Volatility 14.7 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
IGM |
IGM Stock Ownership Analysis
About 35.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.61. IGM Biosciences had not issued any dividends in recent years. IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Igm Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. To learn more about IGM Biosciences call Fred JD at 650 965 7873 or check out https://igmbio.com.IGM Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IGM Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IGM Biosciences backward and forwards among themselves. IGM Biosciences' institutional investor refers to the entity that pools money to purchase IGM Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 223 K | Northern Trust Corp | 2024-09-30 | 191.7 K | Rhenman Partners Asset Management Ab | 2024-09-30 | 185.5 K | Td Asset Management Inc | 2024-09-30 | 164.5 K | Charles Schwab Investment Management Inc | 2024-09-30 | 148.4 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 107.3 K | Bruce & Co Inc | 2024-09-30 | 100 K | D. E. Shaw & Co Lp | 2024-09-30 | 97.7 K | Woodline Partners Lp | 2024-06-30 | 75 K | Baker Bros Advisors Lp | 2024-09-30 | 4.1 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 4.1 M |
IGM Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IGM Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on IGM Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IGM Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IGM Biosciences Outstanding Bonds
IGM Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IGM Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IGM bonds can be classified according to their maturity, which is the date when IGM Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
IGM Biosciences Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 3rd of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.